Literature DB >> 33215052

Dual Checkpoint Blockade in a Neuroendocrine Carcinoma With Dual PD-L1/PD-L2 Amplification and High Tumor Mutational Burden.

Jun Gong1, Sandip Patel2, Jacob J Adashek3, David Frishberg4, Michelle Guan1, Veronica R Placencio-Hickok1, Alexandra Gangi5, Gillian Gresham1, Richard Tuli6, Young K Chae7, Razelle Kurzrock2, Andrew E Hendifar1.   

Abstract

Entities:  

Year:  2020        PMID: 33215052      PMCID: PMC7670562          DOI: 10.1200/PO.18.00391

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN: 2473-4284


× No keyword cloud information.
  25 in total

1.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors:  Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

2.  Characterization of the Neuroendocrine Tumor Immune Microenvironment.

Authors:  Annacarolina da Silva; Michaela Bowden; Sui Zhang; Yohei Masugi; Aaron R Thorner; Zachary T Herbert; Chensheng Willa Zhou; Lauren Brais; Jennifer A Chan; F Stephen Hodi; Scott Rodig; Shuji Ogino; Matthew H Kulke
Journal:  Pancreas       Date:  2018-10       Impact factor: 3.327

3.  PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

Authors:  Stephen M Ansell; Alexander M Lesokhin; Ivan Borrello; Ahmad Halwani; Emma C Scott; Martin Gutierrez; Stephen J Schuster; Michael M Millenson; Deepika Cattry; Gordon J Freeman; Scott J Rodig; Bjoern Chapuy; Azra H Ligon; Lili Zhu; Joseph F Grosso; Su Young Kim; John M Timmerman; Margaret A Shipp; Philippe Armand
Journal:  N Engl J Med       Date:  2014-12-06       Impact factor: 91.245

4.  Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer.

Authors:  Julie George; Motonobu Saito; Koji Tsuta; Reika Iwakawa; Kouya Shiraishi; Andreas H Scheel; Shinsuke Uchida; Shun-Ichi Watanabe; Ryo Nishikawa; Masayuki Noguchi; Martin Peifer; Se Jin Jang; Iver Petersen; Reinhard Büttner; Curtis C Harris; Jun Yokota; Roman K Thomas; Takashi Kohno
Journal:  Clin Cancer Res       Date:  2016-09-12       Impact factor: 12.531

5.  Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

Authors:  Scott J Antonia; José A López-Martin; Johanna Bendell; Patrick A Ott; Matthew Taylor; Joseph Paul Eder; Dirk Jäger; M Catherine Pietanza; Dung T Le; Filippo de Braud; Michael A Morse; Paolo A Ascierto; Leora Horn; Asim Amin; Rathi N Pillai; Jeffry Evans; Ian Chau; Petri Bono; Akin Atmaca; Padmanee Sharma; Christopher T Harbison; Chen-Sheng Lin; Olaf Christensen; Emiliano Calvo
Journal:  Lancet Oncol       Date:  2016-06-04       Impact factor: 41.316

6.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.

Authors:  Garrett M Frampton; Alex Fichtenholtz; Geoff A Otto; Kai Wang; Sean R Downing; Jie He; Michael Schnall-Levin; Jared White; Eric M Sanford; Peter An; James Sun; Frank Juhn; Kristina Brennan; Kiel Iwanik; Ashley Maillet; Jamie Buell; Emily White; Mandy Zhao; Sohail Balasubramanian; Selmira Terzic; Tina Richards; Vera Banning; Lazaro Garcia; Kristen Mahoney; Zac Zwirko; Amy Donahue; Himisha Beltran; Juan Miguel Mosquera; Mark A Rubin; Snjezana Dogan; Cyrus V Hedvat; Michael F Berger; Lajos Pusztai; Matthias Lechner; Chris Boshoff; Mirna Jarosz; Christine Vietz; Alex Parker; Vincent A Miller; Jeffrey S Ross; John Curran; Maureen T Cronin; Philip J Stephens; Doron Lipson; Roman Yelensky
Journal:  Nat Biotechnol       Date:  2013-10-20       Impact factor: 54.908

Review 7.  Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia.

Authors:  Matthias M Weber; Christian Fottner
Journal:  Oncol Res Treat       Date:  2018-04-26       Impact factor: 2.825

8.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.

Authors:  Zachary R Chalmers; Caitlin F Connelly; David Fabrizio; Laurie Gay; Siraj M Ali; Riley Ennis; Alexa Schrock; Brittany Campbell; Adam Shlien; Juliann Chmielecki; Franklin Huang; Yuting He; James Sun; Uri Tabori; Mark Kennedy; Daniel S Lieber; Steven Roels; Jared White; Geoffrey A Otto; Jeffrey S Ross; Levi Garraway; Vincent A Miller; Phillip J Stephens; Garrett M Frampton
Journal:  Genome Med       Date:  2017-04-19       Impact factor: 11.117

Review 9.  Translating insights into tumor evolution to clinical practice: promises and challenges.

Authors:  Matthew W Fittall; Peter Van Loo
Journal:  Genome Med       Date:  2019-03-29       Impact factor: 11.117

10.  FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.

Authors:  Joohee Sul; Gideon M Blumenthal; Xiaoping Jiang; Kun He; Patricia Keegan; Richard Pazdur
Journal:  Oncologist       Date:  2016-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.